Anne Wojcicki Reclaims Leadership of 23andMe
Anne Wojcicki, well-known as one of the founding figures and the former CEO of 23andMe, is in the process of reacquiring significant components of the firm through her nonprofit organization.
After the company filed for Chapter 11 protection earlier this year, Wojcicki's TTAM Research Institute is set to acquire almost all of 23andMe's assets for a price tag of $305 million.
Competitive Bidding
In an unexpected development, Wojcicki intervened with an offer earlier this month, which led to a final round of competitive bidding against Regeneron Pharmaceuticals, a biotechnology firm based in New York. Initially, Regeneron had plans to purchase 23andMe for $256 million.
The Journey of 23andMe
23andMe has made its name primarily through at-home genetic testing kits, a venture that once saw its value soar to around $6 billion. However, the company faced hurdles such as struggling to achieve profitability and dealing with a large-scale data breach in 2023, which resulted in a $30 million lawsuit settlement last year.
New Ownership, New Promises
TTAM has committed to following 23andMe's existing privacy standards and legal regulations. Additionally, the nonprofit has pledged to enhance customer protection and privacy measures by creating a consumer privacy advisory board. This step is set to be completed within 90 days after the transaction's conclusion, pending court authorization, which is anticipated soon.



Leave a Reply